AstraZeneca today confirmed that it delivered 5.3 million doses of its COVID-19 vaccine to the Ministry of Public Health during July, as part of an ongoing commitment to deliver 61 million doses to Thailand as quickly as possible.
The July deliveries meet AstraZeneca’s projections which show that in months with uninterrupted manufacturing, the company can supply between five and six million doses to Thailand.
As of the end of July, AstraZeneca has delivered a total of 11.3 million doses of its COVID-19 vaccine to Thailand, and the company has started delivering to nearby countries from its Thailand supply chain.
James Teague, Country President, AstraZeneca (Thailand) Ltd., said: “Our partner Siam Bioscience is performing amongst the strongest in our worldwide manufacturing network, operating at full capacity and delivering to the highest quality standards. Where possible, we will collaborate with them to deliver vaccines faster. We are proud to be working with Siam Bioscience and helping to bring the people of Thailand on the path to recovery as quickly as possible by supporting the country’s mass vaccination program.”
The vaccine is around 80%-90% effective against severe disease and hospitalisation and is highly effective against all variants of concern, including beta and delta.1,2 Overall safety is comparable to other vaccines.3 Very rare thrombotic events can be treated with early diagnosis and there is no increased risk of very rare thrombotic events after the second dose.4,5
AstraZeneca continues to supply its COVID-19 vaccine globally at no profit during the pandemic period.
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.
For more information about COVID-19 Vaccine AstraZeneca, please visit https://www.azcovid-19.com/asia/th/th.html
For further details please contact Pucharapan Holim, Communications Manager, firstname.lastname@example.org, +66 (0) 86 999 8587.
1. AstraZeneca PLC.COVID-19 Vaccine AstraZeneca confirms 100% protection against severe disease, hospitalisation and death in the primary analysis of Phase III trials. [Online]. Available at: https://www.astrazeneca.com/media-centre/press-releases/2021/covid-19-vaccine-astrazeneca-confirms-protection-against-severe-disease-hospitalisation-and-death-in-the-primary-analysis-of-phase-iii-trials.html [Last accessed: 21 Mar 2021
2. Public Health England COVID-19 vaccine surveillance report Week 20. Available at COVID-19 vaccine surveillance report - week 20 (publishing.service.gov.uk) [Last accessed: July 2021]
3. Public Health England. Effectiveness of COVID-19 vaccines against hospital admission with the Delta (B.1.617.2) variant. Available at: https://khub.net/web/phe-national/public-library/-/document_library/v2WsRK3ZlEig/view/479607266 [Last accessed: July 2021]
4. Burn, E (2021) Thromboembolic events and thrombosis with thrombocytopenia after COVID-19 infection and vaccination in Catalonia, Spain. Pre-print Online: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3886421
5. P. Bhuyan et al. Thrombosis with thrombocytopenia after second AZD1222 dose: a global safety database analysis of rare cases. Lancet. Available at: https://doi.org/10.1016/PII. Accessed July 2021.